• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SCG3 启动子和 ASH1 增强子驱动的 Tat-PTD 修饰溶瘤腺病毒治疗神经母细胞瘤。

Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

机构信息

Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Uppsala SE-75185, Sweden.

出版信息

Hum Gene Ther. 2013 Aug;24(8):766-75. doi: 10.1089/hum.2012.132.

DOI:10.1089/hum.2012.132
PMID:23889332
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3746216/
Abstract

Secretogranin III (SGC3) belongs to the granin family and is highly expressed in endocrine and neural tissues. The human SCG3 promoter has not yet been characterized. We identified that a 0.5-kb DNA fragment upstream of the SCG3 gene can selectively drive transgene expression in neuroblastoma cell lines. The strength of transgene expression was further increased, with specificity maintained, by addition of the human achaete-scute complex homolog 1 (ASH1) enhancer. We developed an oncolytic serotype 5-based adenovirus, in which the SCG3 promoter and ASH1 enhancer drive E1A gene expression. The virus was further modified with a cell-penetrating peptide (Tat-PTD) in the viral capsid, which we have previously shown results in increased adenovirus transduction efficiency of many neuroblastoma cell lines. The virus, Ad5PTD(ASH1-SCG3-E1A), shows selective and efficient killing of neuroblastoma cell lines in vitro, including cisplatin-, etoposide-, and doxorubicin-insensitive neuroblastoma cells. Furthermore, it delays tumor growth and thereby prolonged survival for nude mice harboring subcutaneous human neuroblastoma xenograft. In conclusion, we report a novel oncolytic adenovirus with potential use for neuroblastoma therapy.

摘要

分泌颗粒蛋白 III(SGC3)属于颗粒蛋白家族,在内分泌和神经组织中高度表达。人类 SCG3 启动子尚未被表征。我们发现,SCG3 基因上游的 0.5kb DNA 片段可以选择性地驱动神经母细胞瘤细胞系中转基因的表达。通过添加人 Achaete-scute 复合物同源物 1(ASH1)增强子,进一步增加了转基因的表达强度,同时保持了特异性。我们开发了一种基于溶瘤 5 型腺病毒的病毒,其中 SCG3 启动子和 ASH1 增强子驱动 E1A 基因的表达。该病毒进一步在病毒衣壳中修饰了一个穿透肽(Tat-PTD),我们之前已经证明,这会增加许多神经母细胞瘤细胞系中腺病毒的转导效率。该病毒,Ad5PTD(ASH1-SCG3-E1A),在体外对神经母细胞瘤细胞系具有选择性和高效的杀伤作用,包括对顺铂、依托泊苷和阿霉素不敏感的神经母细胞瘤细胞。此外,它还延迟了肿瘤的生长,从而延长了携带皮下人神经母细胞瘤异种移植物的裸鼠的存活时间。总之,我们报告了一种新型的溶瘤腺病毒,具有用于神经母细胞瘤治疗的潜力。

相似文献

1
Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.SCG3 启动子和 ASH1 增强子驱动的 Tat-PTD 修饰溶瘤腺病毒治疗神经母细胞瘤。
Hum Gene Ther. 2013 Aug;24(8):766-75. doi: 10.1089/hum.2012.132.
2
Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.早期基因增强子-启动子的修饰提高了腺病毒 11 的溶瘤效力。
Mol Ther. 2012 Feb;20(2):306-16. doi: 10.1038/mt.2011.242. Epub 2011 Nov 15.
3
Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.六邻体 Tat 蛋白转导结构域修饰的腺病毒在实验性神经母细胞瘤和神经内分泌肿瘤中表现出增强的治疗效果。
J Virol. 2011 Dec;85(24):13114-23. doi: 10.1128/JVI.05759-11. Epub 2011 Sep 28.
4
Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.膀胱癌特异性重组溶瘤腺病毒在裸鼠皮下异种移植肿瘤模型中的分布与安全性评估。
Curr Gene Ther. 2012 Apr 1;12(2):67-76. doi: 10.2174/156652312800099599.
5
Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.依托泊苷通过自上调多药耐药蛋白1(MDR1)启动子活性增强MDR1驱动的溶瘤腺病毒的抗肿瘤疗效。
Oncotarget. 2015 Nov 10;6(35):38308-26. doi: 10.18632/oncotarget.5702.
6
Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.携带靶向 MYCN 基因短发夹 RNA 的溶瘤腺病毒抑制神经母细胞瘤细胞增殖和体内异种移植肿瘤生长。
J Cancer Res Clin Oncol. 2013 Jun;139(6):933-41. doi: 10.1007/s00432-013-1406-4. Epub 2013 Feb 27.
7
A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.一种survivin介导的溶瘤腺病毒可诱导肺癌细胞发生非凋亡性细胞死亡,并在体内显示出抗肿瘤潜力。
J Gene Med. 2006 Oct;8(10):1232-42. doi: 10.1002/jgm.953.
8
Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.双 E1A 溶瘤腺病毒:利用两个独立的肿瘤特异性启动子元件(DF3/MUC1 和 hTERT)靶向肿瘤异质性。
Cancer Gene Ther. 2011 Mar;18(3):153-66. doi: 10.1038/cgt.2010.52. Epub 2010 Sep 24.
9
E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.具有RGD纤维修饰的E1A、E1B双限制腺病毒对缺乏CAR的胆管癌表现出增强的溶瘤作用。
Clin Cancer Res. 2007 May 15;13(10):3043-50. doi: 10.1158/1078-0432.CCR-06-2103.
10
Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.利用携带 AFP 启动子控制 E1A 和 E1B 缺失以驱动 IL-24 表达的溶瘤腺病毒彻底清除肝癌。
Cancer Gene Ther. 2012 Sep;19(9):619-29. doi: 10.1038/cgt.2012.40. Epub 2012 Jul 13.

引用本文的文献

1
Cell Penetrating Peptides, Novel Vectors for Gene Therapy.细胞穿透肽,基因治疗的新型载体。
Pharmaceutics. 2020 Mar 3;12(3):225. doi: 10.3390/pharmaceutics12030225.
2
Development of novel vaccine vectors: Chimpanzee adenoviral vectors.新型疫苗载体的开发:黑猩猩腺病毒载体。
Hum Vaccin Immunother. 2018 Jul 3;14(7):1679-1685. doi: 10.1080/21645515.2017.1419108. Epub 2018 Jan 23.
3
A novel oncolytic adenovirus based on simian adenovirus serotype 24.一种基于猿猴腺病毒血清型24的新型溶瘤腺病毒。
Oncotarget. 2017 Apr 18;8(16):26871-26885. doi: 10.18632/oncotarget.15845.
4
Trial Watch-Oncolytic viruses and cancer therapy.试验观察——溶瘤病毒与癌症治疗
Oncoimmunology. 2015 Dec 8;5(2):e1117740. doi: 10.1080/2162402X.2015.1117740. eCollection 2016 Feb.
5
Trial Watch:: Oncolytic viruses for cancer therapy.试验观察:用于癌症治疗的溶瘤病毒
Oncoimmunology. 2014 Jun 1;3:e28694. doi: 10.4161/onci.28694. eCollection 2014.

本文引用的文献

1
Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.经 Tat-PTD 修饰的五型腺病毒载体和 35 型纤维的五型腺病毒载体显著提高了原代细胞培养物的转导能力。
PLoS One. 2013;8(1):e54952. doi: 10.1371/journal.pone.0054952. Epub 2013 Jan 25.
2
Virotherapy of neuroendocrine tumors.神经内分泌肿瘤的病毒治疗。
Neuroendocrinology. 2013;97(1):26-34. doi: 10.1159/000336084. Epub 2012 Feb 29.
3
Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.联合 MDR1 靶向复制型腺病毒和化疗治疗预处理的卵巢癌。
J Cancer Res Clin Oncol. 2012 Apr;138(4):603-10. doi: 10.1007/s00432-011-1135-5. Epub 2012 Jan 1.
4
Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.六邻体 Tat 蛋白转导结构域修饰的腺病毒在实验性神经母细胞瘤和神经内分泌肿瘤中表现出增强的治疗效果。
J Virol. 2011 Dec;85(24):13114-23. doi: 10.1128/JVI.05759-11. Epub 2011 Sep 28.
5
Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells.腺病毒治疗在吉西他滨耐药的胰腺癌中比在吉西他滨敏感的细胞中更有效。
Anticancer Res. 2011 Apr;31(4):1279-87.
6
Recent advances in neuroblastoma.神经母细胞瘤的最新进展
N Engl J Med. 2010 Jun 10;362(23):2202-11. doi: 10.1056/NEJMra0804577.
7
Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II.人神经内分泌肿瘤中的分泌粒蛋白III:与嗜铬粒蛋白A、B及分泌粒蛋白II的比较性免疫组织化学研究
Regul Pept. 2010 Nov 30;165(1):30-5. doi: 10.1016/j.regpep.2010.06.002. Epub 2010 Jun 12.
8
Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?溶瘤单纯疱疹病毒载体与化疗:联合策略对癌症更有效吗?
Future Oncol. 2010 Apr;6(4):619-34. doi: 10.2217/fon.10.18.
9
Neuroblastoma: Therapeutic strategies for a clinical enigma.神经母细胞瘤:临床难题的治疗策略。
Cancer Treat Rev. 2010 Jun;36(4):307-17. doi: 10.1016/j.ctrv.2010.02.006. Epub 2010 Mar 12.
10
Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.自体间充质干细胞介导的系统溶瘤病毒治疗转移性神经母细胞瘤:一项探索性研究。
Cancer Gene Ther. 2010 Jul;17(7):476-83. doi: 10.1038/cgt.2010.4. Epub 2010 Feb 19.